Showing 1,721 - 1,740 results of 101,391 for search '(( 12 nm decrease ) OR ( 5 ((((we decrease) OR (a decrease))) OR (teer decrease)) ))', query time: 1.33s Refine Results
  1. 1721
  2. 1722

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  3. 1723

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  4. 1724

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  5. 1725

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  6. 1726

    Discovery of Novel [1,2,4]Triazolo[1,5‑<i>a</i>]pyrimidine Derivatives as Novel Potent S‑Phase Kinase-Associated Protein 2 (SKP2) Inhibitors for the Treatment of Cancer by Kaizhao Hu (15670612)

    Published 2024
    “…Pharmacological inhibition of Skp2 has exhibited promising antitumor activity. Herein, we present the design and optimization of a series of [1,2,4]triazolo[1,5-<i>a</i>]pyrimidine-based small molecules targeting Skp2. …”
  7. 1727
  8. 1728
  9. 1729
  10. 1730

    Activin A decreases MPTP and LPS-induced inflammation. by Sandy Stayte (728461)

    Published 2017
    “…<p>Stereological quantification of the left SNpc demonstrated activin A significantly decreased the number of GFAP-immunoreactive cells (A) and Iba1-immunoreactive cells (B) in the SNpc following MPTP. …”
  11. 1731

    Grey matter concentration decreases for (A) tinnitus duration. by Sven Vanneste (202029)

    Published 2015
    “…<p>Grey matter decrease projected onto a T1-weighted image. Maximum intensity projection with a threshold of <i>p</i> < .001 (uncorrected) at both voxel and cluster level. …”
  12. 1732
  13. 1733
  14. 1734
  15. 1735
  16. 1736
  17. 1737
  18. 1738
  19. 1739

    Table 5_The impact of decreased prognostic nutritional index on the prognosis of patients with pneumonia treated with glucocorticoids: a multicenter retrospective cohort study.docx by Fengwang Xue (22245625)

    Published 2025
    “…The ACM rates were 22.5% at 30 days and rose to 26.0% at 90 days. Multivariable Cox regression showed that, after full adjustment for potential confounders, every 2-unit decrease in PNI was associated with a 10% higher 30-day mortality hazard (HR = 1.10, 95% CI = 1.05–1.15, p < 0.001) and a 9% higher 90-day mortality hazard (HR = 1.09, 95% CI = 1.04–1.14, p < 0.001). …”
  20. 1740